Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …

Although the impact of tumor immunology on the clinical management of most cancers is still
negligible, there is increasing evidence that anticancer immune responses may contribute to …

Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

Over the last few decades, various forms of regulated cell death (RCD) have been
discovered and were found to improve cancer treatment. Although there are several reviews …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has
achieved considerable success in the clinic. However, ICIs are significantly limited by the …

Death is the inevitable fate of all living organisms, whether at the individual or cellular level.
For a long time, cell death was believed to be an undesirable but unavoidable final outcome …

Cancer is the deadliest disease in the world behind heart disease. Sadly, this remains true
even as we suffer the ravages of the Covid-19 pandemic. Whilst current chemo-and …